Here we present evidence that (+)-
avrainvillamide, a naturally occurring
alkaloid with antiproliferative effects, binds to the nuclear chaperone
nucleophosmin, a proposed oncogenic
protein that is overexpressed in many different human
tumors. Among other effects,
nucleophosmin is known to regulate the
tumor suppressor protein p53. A synthetic
biotin-
avrainvillamide conjugate, nearly equipotent to the
natural product in inhibiting the growth of cultured T-47D cells, was used for affinity-isolation of a
protein identified as
nucleophosmin by MS sequencing and Western-blotting. Affinity-isolation of
nucleophosmin was inhibited in the presence of
iodoacetamide (10 mM), free (+)-
avrainvillamide (100 microM), and a series of closely related structural analogues of (+)-
avrainvillamide, the latter with inhibitory effects that appear to correlate with measured growth-inhibitory potencies. Using fluorescence microscopy, a synthetic
dansyl-
avrainvillamide conjugate was observed to localize within the nucleoli and the cytosol of treated
cancer cells. Site-directed mutagenesis of each of the three
cysteine residues of a truncated
nucleophosmin coexpressed with native
nucleophosmin in COS-7 cells revealed that the mutation cys275 --> ala275 effectively and uniquely reduced affinity-isolation of the truncated
protein, suggesting that
avrainvillamide targets cys275 of
nucleophosmin. Finally, we show that treatment of adhered LNCaP or T-47D cells with (+)-
avrainvillamide leads to an increase in cellular p53 concentrations, and that
siRNA-promoted depletion of
nucleophosmin in a population of HeLa S3 cells leads to increased sensitivity of that population toward apoptotic death upon treatment with (+)-
avrainvillamide. Although potentially desirable as lead compounds for the development of novel anticancer
therapies, nonpeptidic, synthetic small molecules that bind to
nucleophosmin have not been described, prior to this report.